JonathanAGutmanMD

Hematologic Oncology

Assistant Professor, Medicine, University of Colorado School of Medicine

Overview of Dr. Gutman

Dr. Jonathan Gutman is an oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. He received his medical degree from New York University Grossman School of Medicine and has been in practice 15 years. He is one of 128 doctors at University of Colorado Hospital who specialize in Oncology. He has more than 80 publications and over 500 citings.

Office
12605 E 16th Ave
Aurora, CO 80045
Book by Phone+1(920) 250-9137

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2008
University of ColoradoResidency, Internal Medicine, 2002 - 2005
New York University School of MedicineClass of 2002

Certifications & Licensure

CO State Medical License 2004 - 2025
WA State Medical License 2006 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies Start of enrollment: 2006 Apr 01
Completed
Phase 1
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Start of enrollment: 2005 Nov 18
Active, not recruiting
Phase 2
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Jun 25
Completed
Phase 2
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Start of enrollment: 2009 Feb 24
Completed
Phase 2
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Start of enrollment: 2009 Feb 01
Completed
Phase 2
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2011 Jan 25
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Start of enrollment: 2012 Dec 11
Completed
Phase 2
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Dec 06
Completed
Phase 2
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
The Chimerix CMX001 Registry Start of enrollment: 2014 Jan 01
Terminated
Join now to see all

Publications & Presentations

PubMed

Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
Kellen B Gil, Diana Abbott, Maria L Amaya, Marc Schwartz, Jonathan A Gutman
Leukemia & Lymphoma. 2024-12-01
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders.
Dimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, Roland Schroers, Aiden Haghikia
Cytotherapy. 2024-10-05
Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis.
Andrew Kent, Kellen B Gil, Michael K Jones, Brooke Linden, Enkhee Purev
Transplantation and Cellular Therapy. 2024-08-17

Journal Articles

Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia
Daniel A Pollyea, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Nature

Abstracts/Posters

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
Jonathan A Gutman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...
Jonathan A Gutman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide ...
Jonathan A Gutman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...
Jonathan A Gutman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Re...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Cord Blood Outperforms Matched, Unrelated Donor in Bone Marrow TransplantJuly 26th, 2016
Supporting a House Bill That Would Improve Access to Clinical Trials for EveryoneFebruary 16th, 2024
Champions for Their Patients: 21 Inducted into CU Department of Medicine’s New Clinical Excellence SocietyFebruary 29th, 2024
Join now to see all